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In principle, the statistical considerations that
apply in late-effect studies are no different than those
that arise in any kind of clinical study. Nevertheless,
there are features that arise in such studies that require
careful consideration to best analyze and interpret the
data at hand. We do not intend here to consider all
possible issues, but will focus on a few that are
important and that have come to our attention during
the course of many collaborations with studies of this
kind.EXAMPLE—TEMPORAL ORDERING AND
TIME-DEPENDENT EFFECTS
In the setting of hematopoietic cell transplant
(HCT), late effects are common, and cannot be appro-
priately analyzed without careful consideration of the
temporal ordering of these effects, particularly when
1 outcome may be used to predict another. One must
also carefully consider the appropriate populations of
survivors, or those ‘‘at risk,’’ during the time period
of interest. One of the classic examples where these
issues come into play in the HCT setting is the evalu-
ation of ‘‘graft-versus-tumor’’ (GVT) effects—that is,
the hypothesis that patients who develop chronic
graft-versus-host disease (cGVHD) have more favor-
able outcomes (lower rates of relapse and death) com-
pared to those who do not. Here, cGVHD relapse, and
death are all late effects, and the interest is in defining
the association between cGVHD and the other 2 ef-
fects.
In 322 patients undergoing HCT after nonmyeloa-
blative conditioning, described in Baron et al. [1],Fred Hutchinson Cancer Research Center, Seattle,
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transplant and did not develop in the remaining 144
patients. In the latter group, 78% relapsed or died,
compared to 40% in the group with cGVHD. A
relatively common but erroneous approach to evaluat-
ing the impact of cGVHD on relapse and death is to
divide the patient population according to whether
cGVHD did or did not occur posttransplant, and plot
relapse-free survival (RFS) from the time of transplant
(Figure 1). This plot suggests that the occurrence of
cGVHD is associated with markedly better outcome,
and a hazard ratio (HR) analysis comparing the rate
of relapses and deaths in the group with cGVHD to
the rate in the group without cGVHD yields a highly
statistically significant result (HR 5 0.25, 95% confi-
dence interval [CI] 0.18-0.35, P\ .0001).
The problem with this analysis is that it does not
accurately consider the temporal patterns of these
late effects and the dynamic patient population at
risk. For example, although most cGVHD develops
3-12 months after transplant, many deaths and relapses
may occur prior to this time. The patients undergoing
these earlier events never had the opportunity
to develop cGVHD. Conversely, patients developing
cGVHD had to live a minimal period of time before
they were at risk of developing this late effect.
A partial solution to this problem is the so-called
‘‘landmark’’ analysis, which classifies patients based
on their prior history of cGVHD at a fixed point in
time, and then looks at deaths and relapses that occur
subsequent to this point. Patients who have died or re-
lapsed prior to the landmark time are not included in
the analysis, and the occurrence of cGVHD after the
landmark time is not used to classify patients. For the
current example, a landmark time of 6 months post-
transplant yields 189 patients who are alive and disease
free at that time. Of these, 100 patients had prior onset
of cGVHD and 32% relapsed or died after 6 months.
Of the 89 patients without prior cGVHD at 6 months,
33% subsequently relapsed or died (Figure 2).
The figure and HR analysis, using only the post-
landmark events, now suggest no association between
cGVHD and relapse or death (HR 5 0.96, 95% CI
0.58-1.58, P 5 .86).25
Figure 1. Biased estimates of progression-free survival (PFS), grouping
patients according to whether they ever had cGVHD (solid black line) or
not (solid gray line), and estimating PFS after transplant. Tick marks
indicate censoring at last contact.
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complete use of the data. Deaths or relapses occurring
before 6 months, among patients who also developed
cGVHD before 6 months, are not accounted for. Sim-
ilarly, cGVHD that develops after 6 months is not
accounted for. To incorporate information from these
events, the most appropriate analytic approach is to
treat cGVHD as a ‘‘time-dependent’’ factor in the
HR analysis. In this way, at each point in time, only
patients still at risk for subsequent death or relapse are
considered, and these patients are classified with
respect to cGVHD on the basis of the prior develop-
ment of this late effect. In effect, this strategy considers
all possible landmark times, and summarizes the com-
parison across these times. In the current example, an
HR analysis of cGVHD as a time-dependent covariate
is consistent with a modest GVT effect (HR 5 0.60,
95% CI 0.40-0.91, P 5 .02). Unfortunately, this
association is difficult to illustrate graphically. Al-
though it is straightforward to plot RFS after the onset
of cGVHD, there is no convenient and comparable
point of reference for those that do not develop
cGVHD.Figure 2. Estimates of PFS based on a landmark analysis at 6 months,
grouping patients that are alive and disease free at that time according
to whether they previously had cGVHD (solid black line) or not (solid
gray line), and estimating PFS after 6months. Tickmarks indicate censor-
ing at last contact.EXAMPLE—ASCERTAINMENTOF LATE
EFFECTS
Another important issue in the study of late effects
is the ascertainment of the effect, and just as impor-
tantly, the ascertainment of the absence of the effect.
In general, it may be easier to establish that a late effect
is present than to establish with confidence that it is
absent. This is particularly true if the absence of the
late effect is not necessarily clinically manifest, but
must be ascertained through a diagnostic evaluation,
for example, low bone mineral density or high choles-
terol. Even when the late effect is defined by a relativelyobvious clinical presentation, such as myocardial
infarction, the declaration that such an effect is absent
in a patient cannot be made without regular follow-up
information. Conversely, it is just as problematic when
the absence of follow-up may be associated with the
occurrence of the late effect, that is, what is called
‘‘informative censoring.’’ These issues become
compounded if the predictors of late effects differen-
tially affect the components of ascertainment and
follow-up.
Sanders et al. [2] report on a study of thyroid dys-
function in a cohort of 791 pediatric HCT recipients
who survived at least 1 year. Some of these patients
were followed for up to 30 years. Although thyroid
dysfunction can be associated with clinical symptoms,
the demonstration of normal thyroid function in
asymptomatic patients requires a diagnostic evalua-
tion. The data that were available for analysis included
the time of a diagnosis of thyroid dysfunction, the time
of last contact for all patients, and the time of last
known normal thyroid evaluation, for patients that
did not develop thyroid dysfunction. Among the 553
patients that did not have diagnosed thyroid dysfunc-
tion, the gap between the last known normal thyroid
evaluation and the date of last contact or death varied
from 0 to nearly 29 years, with a median gap of 4.2
years.
Figure 3 plots the cumulative incidence of thyroid
dysfunction under 2 different assumptions: (1) that
patients without diagnosed disease were free of disease
until the date of last contact or death, or (2) that
patients were only free of disease until the time of
the last normal thyroid evaluation, and are censored
at that time. In both cases, death without diagnosed
thyroid dysfunction is treated as a competing risk.
These 2 assumptions produce spectacularly different
estimates of the incidence of thyroid abnormality; for
Figure 3. Cumulative incidence of thyroid abnormality under the as-
sumption that patients remain normal until last contact (solid black
line), or are censored at the time of last normal evaluation (solid gray
line).
Figure 5. Cumulative incidence of death without thyroid abnormality
under the same assumptions as shown in Figure 4.
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estimates are 33% and 57%, respectively. Clearly,
the former estimate likely misses some incident events
that were not detected because the patient was not
evaluated. Just as clearly, the latter estimate takes too
strict an approach to determining the absence of
abnormality, and does not account for the fact that
subsequent deaths without thyroid abnormality will
remove patients from the set of patients at risk.
To evaluate which of these curves might be more
realistic we performed a sensitivity analysis using 2 in-
termediate assumptions about the interpretation of the
last normal thyroid evaluation, that is, that a normal
evaluation was assumed to mean absence of disease
for up to 1 year or 5 years following the actual evalua-
tion (Figure 4). We also considered the impact of
these assumptions on the incidence of the competing
risk of death without thyroid dysfunction (Figure 5).
Although it is not possible to determine which of these
results is correct, it does seem that the more conserva-Figure 4. Cumulative incidence of thyroid abnormality under differing
assumptions. Solid black and gray lines are as described for Figure 3. In-
termediate lines assume patients are normal for up to 1 year after last
normal evaluation (long dashes, gray line) or for up to 5 years after
last normal evaluation (short dashes, gray line)tive assumptions regarding the meaning of a normal
thyroid evaluation result in unreasonably high esti-
mates of the incidence of thyroid abnormality and
unreasonably low estimates of the incidence of death
without thyroid abnormality.
In the paper, rather than introduce an arbitrary
assumption about the interpretation of a normal
thyroid evaluation, we simply assumed that such
patients were normal until death or last contact, with
the understanding that the incidence of ‘‘detected thy-
roid abnormality’’ would necessarily underestimate the
true incidence. Fortunately, these assumptions had
little impact on the evaluation of risk factors for thyroid
dysfunction. This is not a generally valid result, if
known risk factors for late effects are associated with
differential frequency of follow-up evaluations. An
example of such a situation would be a study of pulmo-
nary function abnormalities detected by a pulmonary
function test (PFT). Some centers routinely administer
PFTs to patients with cGVHD, which is also associated
with pulmonary dysfunction. In such a setting it would
be almost impossible to estimate the true impact of
cGVHD on pulmonary complications, because pa-
tients with cGVHD would be screened more often
than those without.
Other difficult issues that arise in late effects studies
include data that are missing in an informative way, for
example, when ill patients decline to complete quality-
of-life assessments, or comparison of the incidence of
late effects in a population of HCT survivors to that
in a normal population. As in the examples described
above, meaningful design, analysis, and interpretation
of such studies requires careful consideration of the tim-
ing of the late effects, the population from which they
arise, and the manner of ascertainment.ACKNOWLEDGMENTS
Financial disclosure: The author has nothing to
disclose.
28 Biol Blood Marrow Transplant 15:25-28, 2009B. E. StorerREFERENCES
1. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor ef-
fects after allogeneic hematopoietic cell transplantation with non-
myeloablative conditioning. J Clin Oncol. 2005;23:1993-2003.2. Sanders JE, Hoffmeister P, Woolfrey AE, Carpenter PA,
Storer BE, Appelbaum FR. Thyroid function following
hematopoietic cell transplantation: 30 years experience. Blood
(in press).
